Leadership & Board

Ofer Haviv holds the position of Evogene’s (Nasdaq: EVGN) President and CEO as of late 2004. Prior to that, he held the positions of company COO and CFO from 2002 to 2004, and was involved in Evogene’s spin-off from Compugen (NASDAQ: CGEN) in 2002. At Compugen, he held the position of Director of Finance and Treasurer for four years, during which time the company completed two private placements and an IPO on NASDAQ
Mr. Haviv holds a B.A. degree in Economics and Accounting from the Faculty of Management, Tel Aviv University, and is a Certified Public Accountant in Israel.

Dr. Bao is a partner of Shanghai Healthcare Capital (SHC), with more than 30 years of experience in cancer research, infectious disease control, fund management and drug clinical trials. Prior to joining SHC, Dr. Bao worked for 14 years at the National Institute of Health (NIH) in the United States, where she also directed and managed NIH’s global clinical trial projects in the field of infectious diseases. Dr. Bao also served as the Chief Medical Officer for large pharmaceutical and biotech companies. He holds a doctorate degree from the Weizmann Institute of Science in Israel, and an MD degree from Southeast University’s Medical School.

Doron is a seasoned executive with more than 20 years of management experience in the biotech industry. He is the founder and managing director of Triticum, a startup company that is developing a clot retriever device for the treatment of stroke and occlusions in peripheral vessels. He previously held a range of executive positions, including Associate Vice President for the Eastern European and Israel region at Merck (MSD), Managing Director of the Merck subsidiary in Israel, and General Manager of Lundbeck Israel.
Doron also acts as a consultant to several pharma and medical device companies.
He holds a Master of Health Systems Administration degree (M.H.A.) from Tel Aviv University, Israel.

Mr. Yaron Eldad serves as the CFO at Evogene.
Mr. Eldad has filled various CFO positions over the last 25 years in public and private technology and biotechnology companies, including Yamba Group Int. Ltd., Recoly NV, and e-Sim Ltd.
Mr. Eldad holds a B.A. in Economics and Accounting from the Ben-Gurion University, Israel, an Executive MBA in Strategic Management from the Hebrew University, Israel, and an M.A. in law from the Bar-Ilan University, Israel.